Find a company by name or ticker and open its page
We use analytics cookies to understand how you use Stockoscope and improve the platform. Essential cookies that keep you logged in are always on. Cookie policy
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
AMGNThe Motley FoolAmgen's cancer drug Imdelltra has been shown to be effective in treating advanced lung cancer when paired with AstraZeneca's Imfinzi. The risk of death was cut by 58% for patients who used the combination treatment.
Also in the news
Zacks Investment Research
247 Wallst
Zacks Investment Research
AMGN24/7 Wall StreetAmgen (NASDAQ:AMGN | AMGN Price Prediction) is expected to report third-quarter results on Tuesday, November 3, after the close. The stock is up 41.28% year to date, and management has already warned that spending will jump.
AMGNZacks Investment ResearchBeyond analysts' top-and-bottom-line estimates for Amgen (AMGN), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.
AMGNPRNewsWireTHOUSAND OAKS, Calif., Oct. 28, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its third quarter 2026 financial results on Tuesday, November 3, 2026, after the close of the U.S. financial markets.
AMGNZacks Investment ResearchAmgen heads into Q3 earnings with a four-quarter beat streak, but biosimilar competition, pricing pressure and higher costs may challenge growth.
AMGNPRNewsWire/PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the fourth quarter of 2026. The
AMGNPRNewsWirePhase 3 OASIZ-301 Study of Dazodalibep in Sjögren's Disease Shows Statistically Significant and Clinically Meaningful Improvement in Systemic Disease Activity and Patient-Reported Dryness New Long-Term UPLIZNA Data in IgG4-Related Disease and Real-World Evidence for KRYSTEXXA and TAVNEOS Further Highlight Amgen's Broad Portfolio and Commitment to People Living with Rare Diseases THOUSAND OAKS, Calif., Oct. 27, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to present new data across its portfolio, including in rare and other serious autoimmune diseases at the American College of Rheumatology (ACR) Convergence 2026.
AMGNThe Motley FoolAmgen currently looks stronger on revenue by generating a consistently larger top line in absolute terms compared to Vertex Pharmaceuticals across every observed quarter. Over roughly the last eight quarters, Amgen demonstrated moderate quarter-over-quarter revenue fluctuations, while Vertex Pharmaceuticals maintained a very steady and gradual upward revenue trend.
AMGNThe Motley FoolAmgen maintains a robust presence in oncology and rare diseases with a 9.9% revenue growth rate in FY 2025. Novo Nordisk continues to dominate the global diabetes and obesity markets with a high net margin of 33.1%.
AMGNZacks Investment ResearchAmgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.